The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
EMA recommended 30 veterinary medicines for marketing authorisation in 2025
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
Experts caution that realizing AI’s potential requires careful management and risk mitigation
Subscribe To Our Newsletter & Stay Updated